Annual general meeting

Addex Shareholders Approve All Resolutions at Annual General Meeting

Retrieved on: 
Thursday, June 1, 2023
Bank statement, Execution management system, LR, AGM, Article, BDO, Senior, Annual report, Articles of association, Annual general meeting, Management

53 LR

Key Points: 
  • 53 LR
    Geneva, Switzerland, June 1, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”), announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2023 Annual General Meeting (AGM).
  • Addex shareholders approved the 2022 annual report, the 2022 annual financial statements, the appropriation of the results as well as the compensation report (the latter in a consultative vote).
  • BDO SA were re-elected as the auditors for the 2023 business year and Robert P. Briner, attorney-at-law, was re-elected as the independent voting rights representative until the 2024 Annual General Meeting.
  • Addex shareholders also approved the amendments of the Articles of Association.

JANA Partners Files Lawsuit to Stop Freshpet Board’s Highly Entrenching Actions Intended to Disenfranchise Shareholders and Manipulate Shareholder Vote

Retrieved on: 
Thursday, June 1, 2023
Consulting, Consumer, Professional Services, Pets, Legal, Exercise, Delaware Court, Meeting, Complaint, JANA, Annual general meeting, JANA Partners LLC, Management, Shareholder, Freshpet

JANA Partners (“JANA”), which along with its affiliates and partners owns 9.5% of Freshpet, Inc. (NASDAQ:FRPT) (“Freshpet” or the “Company”), today filed a complaint in the Court of Chancery of the State of Delaware (the “Court”) against Freshpet and the Company’s Board of Directors (the “Board”).

Key Points: 
  • JANA Partners (“JANA”), which along with its affiliates and partners owns 9.5% of Freshpet, Inc. (NASDAQ:FRPT) (“Freshpet” or the “Company”), today filed a complaint in the Court of Chancery of the State of Delaware (the “Court”) against Freshpet and the Company’s Board of Directors (the “Board”).
  • JANA has also filed a motion to expedite these proceedings to resolve this critical issue ahead of the recently-advanced deadline to nominate directors for consideration at the Meeting.
  • In our view, the Board's blatant misuse of corporate machinery obstructs the legitimate efforts of shareholders to exercise their rights and cannot stand.
  • Shareholders with questions can contact JANA’s proxy solicitor, Innisfree M&A Incorporated, at (212) 750-5833.

MKT Capital Calls on Aurinia’s Board of Directors to Respect the Message Sent by Shareholders at 2023 Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
Other Professional Services, Professional Services, Finance, Fear, Annual Meetings of the International Monetary Fund and the World Bank Group, Merrell Dow Pharmaceuticals Inc. v. Thompson, Sale, Capital, Annual general meeting, MKT, Policy, Compensated emancipation, Management, Aurinia

At the Annual Meeting, Chairman George Milne and Compensation Committee Chair Joseph Hagan received less than majority support from shareholders and subsequently submitted their resignations to the Board of Directors (the “Board”) pursuant to the Company’s Majority Voting Policy.

Key Points: 
  • At the Annual Meeting, Chairman George Milne and Compensation Committee Chair Joseph Hagan received less than majority support from shareholders and subsequently submitted their resignations to the Board of Directors (the “Board”) pursuant to the Company’s Majority Voting Policy.
  • “It has been two full weeks since shareholders sent a clear message for immediate change in Aurinia’s boardroom.
  • This unjustifiable delay further illustrates the Board’s blatant disregard for shareholders’ wishes and proclivity for issuing misleading communications.
  • We have engaged with a large number of shareholders who fear additional dilution and would strongly favor a sale of the business at the right price.

Universal Display Corporation to Hold Virtual 2023 Annual Meeting of Shareholders

Retrieved on: 
Thursday, June 1, 2023
Consumer Electronics, Technology, Professional Services, Semiconductor, Research, Nanotechnology, Alternative Energy, Energy, Science, Hardware, Finance, Online, Lighting, Annual Meetings of the International Monetary Fund and the World Bank Group, Universal Display Corporation, UDC, Annual general meeting, Company secretary, OLED, Internet, Television, Online shopping

Universal Display Corporation (Nasdaq: OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, will hold its 2023 Annual Meeting of Shareholders in a virtual-only format beginning at 10:00 A.M. Eastern Time on Thursday, June 15, 2023.

Key Points: 
  • Universal Display Corporation (Nasdaq: OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, will hold its 2023 Annual Meeting of Shareholders in a virtual-only format beginning at 10:00 A.M. Eastern Time on Thursday, June 15, 2023.
  • To attend and participate in the Annual Meeting, shareholders of record as of the close of business on April 10, 2023, will need to visit www.virtualshareholdermeeting.com/OLED2023 and log in using the 16-digit control number found on their proxy card, voting instruction form or notice of internet availability.
  • Guests may attend the 2023 Annual Meeting in a listen-only mode.
  • Participants should allow plenty of time to log in prior to the start of the Annual Meeting.

Sarah Cannon Research Institute to Present Latest Oncology Research Insights at 2023 ASCO® Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
Science, Health, Oncology, Research, Head, Lead, FACOG, DO, HealthOne, Colorectal cancer, Spacecraft, Sarah Cannon Research Institute, Otorhinolaryngology, Coronation of the British monarch, Atezolizumab, McKesson Corporation, Cancer, Sunitinib, Breast, MS, Adjuvant, Carcinoma, Randomness, Conjugation, Phase, Combination, Abstract, Metastasis, SCRI, HR, Kidney, MPH, Doctor of Pharmacy, Highlight, Lung, ASCO, Potent, American Society of Clinical Oncology, Physician, FRA, Annual general meeting, FACS, Thomas Jefferson National Accelerator Facility, CDT, Society, Sodium-dependent phosphate transport protein 2B, Nursing, Pharmaceutical industry, Music, Medical imaging, Safety, E450, MD, Pharmacokinetics, Pembrolizumab, Master of Medicine, Efficacy, Patient

Sarah Cannon Research Institute (SCRI) announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting June 2-6, 2023.

Key Points: 
  • Sarah Cannon Research Institute (SCRI) announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting June 2-6, 2023.
  • In 2022, SCRI joined together with US Oncology Research as one company to transform oncology research and improve care in more than 24 states across the U.S. Operating as SCRI, the unified research network has over 1,300 physicians enrolling patients to more than 1,000 trials annually.
  • “The collaborations across SCRI’s expanded network are accelerating progress and serving more patients closer to where they live,” says Howard A.
  • “We are looking forward to this year’s Annual Meeting where we will be discussing the results of trials that are advancing therapies across a variety of cancers.”
    For a comprehensive list of abstracts and presentations, click here .

Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
Mental Health, FDA, Public Relations, Investor Relations, Communications, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Central nervous system, Depression, Anxiety, COVID-19, Fear, Woman, SAD, Headache, CNS, ASCP, Patient, LSAS, Annual general meeting, Social anxiety disorder, Poster, PH94B, Mental health, Society, Safety, Pharmaceutical industry, Nursing, Medical imaging

Over 30,000 doses of fasedienol were administered by patients during the study.

Key Points: 
  • Over 30,000 doses of fasedienol were administered by patients during the study.
  • The LSAS was the primary efficacy endpoint in all registration studies for the three FDA-approved treatments for adults with SAD.
  • The CGI-I results indicated 43% of the 218 patients assessed after three months were “much” or “very much” improved.
  • The PGI-C results indicated 44% of the 218 patients assessed after three months considered themselves “much” or “very much” improved.

Ivonescimab Updated Data to be Featured at ASCO 2023

Retrieved on: 
Thursday, June 1, 2023
Oncology, Medical Supplies, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Metastasis, Sun, Lung cancer, TKI, NSCLC, Central Time, Paranal Observatory, Immunotherapy, Trial of the century, ASCO, VEGF, HKEX, American Society of Clinical Oncology, Patient, EGFR, Anaplastic lymphoma kinase, TME, Annual general meeting, SMMT, Poster, PD-1, Phase, Summit, Tumor microenvironment, Society, Safety, ALK, Pharmaceutical industry, Medical imaging

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
  • The poster with updated clinical data from Phase II clinical trials will be displayed on Sunday June 4 from 8:00 to 11:00am Central Time during the Lung Cancer – Non-Small Cell Metastatic Poster Session.
  • The poster provides updated data supporting promising anti-tumor activity of ivonescimab in first line advanced or metastatic NSCLC, while displaying that ivonescimab may have an acceptable safety profile in combination with platinum-doublet chemotherapy for patients with squamous or non-squamous advanced or metastatic NSCLC in this clinical study.
  • Over 750 patients have been treated with ivonescimab across multiple clinical studies in different indications in China and Australia.

Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
Science, Other Science, Biotechnology, Research, Oncology, General Health, Health, Genetics, Abstract, DNA, Circulating tumor DNA, Drug development, ICI, Classification, HIC, Lung cancer, Prescription, NSCLC, Government, ASCO, Organization, Friends, Data analysis, American Society of Clinical Oncology, Patient, Annual general meeting, Diagnosis, Poster, Friends of Cancer Research, Neoplasm, Society, Medical imaging, Medical device

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR) featuring genomic data contributed by Biodesix and other organizations.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR) featuring genomic data contributed by Biodesix and other organizations.
  • The new data release indicates that ctDNA shows promise as an early endpoint to support drug development and regulatory decision-making.
  • “We are thrilled to partner with our colleagues in industry, academia, government and Friends of Cancer Research in contributing to the new data analysis on ctDNA and outcomes that will be released at the ASCO 2023 Annual Meeting,” said Gary Pestano, Chief Development Officer of Biodesix.
  • These analyses evaluated healthcare resource utilization (HCRU) and healthcare costs in patients with non-small cell lung cancer (NSCLC) classified by the test.

Tempus Announces Broad Launch of Tempus One

Retrieved on: 
Thursday, June 1, 2023
Data Management, Practice Management, Technology, Managed Care, Health, Health Technology, Apps, Applications, Software, Artificial Intelligence, Hospitals, Mobile, Wireless, UC San Diego Health, Intelligence, Human, Multimedia, Biomarker, Incidence, UC, Patient, Physician, Medicine, Annual general meeting, Artificial intelligence, Diagnosis, Medical device, Tempus, MD

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced the upcoming broad launch of Tempus One – the first, AI-enabled clinical assistant that leverages advancements in generative AI to provide clinicians access to patient insights directly at their fingertips.

Key Points: 
  • Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced the upcoming broad launch of Tempus One – the first, AI-enabled clinical assistant that leverages advancements in generative AI to provide clinicians access to patient insights directly at their fingertips.
  • As an early adopter of generative AI, Tempus originally unveiled the first prototype of Tempus One in early 2021 and subsequently enrolled a cohort of clinicians into a pilot program as provisional beta users.
  • The beta test revealed that Tempus’ clinician users preferred to use the Tempus One technology on existing devices, including desktops and mobile apps, versus the initial cube prototype.
  • Tempus One will be available through the Tempus Hub platform later this year.

Sengenics Spotlights Research From NYU on Predicting Immune-Related Adverse Events (irAEs) at ASCO Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
Health Technology, Health, Oncology, Biometrics, ICI, New York University Grossman School of Medicine, NYU, New York University, Research, Melanoma, ASCO, Corporation, Patient, Annual general meeting, Abstract, Dean (education), Pharmaceutical industry, Vaccine, Robert Ira Lewy, Kusado Sengen, Medicine

The predictive antibody data were generated with the Sengenics immunoprofiling platform.

Key Points: 
  • The predictive antibody data were generated with the Sengenics immunoprofiling platform.
  • The emergence of immune checkpoint inhibitors has revolutionized cancer treatment by effectively countering cancer cells’ suppression of the cytotoxic T-cell response.
  • Dr. Osman’s research investigates the hypothesis that patients susceptible to irAEs may exhibit baseline antibody profiles that hold predictive value for their response.
  • Her primary focus revolves around conducting translational research in melanoma where she spearheads the Melanoma Research Enterprise at NYU.